Retatrutide side effects rise with dose in the Ozempic head to head trial

Retatrutide side effects are the cost attached to the strongest head to head result yet for Eli Lilly's weekly triple agonist. In TRANSCEND-T2D-2, both doses beat the highest approved Ozempic dose on blood sugar and roughly doubled its weight loss over 80 weeks, according to Lilly's topline release on October 28. More people on retatrutide also stopped treatment because of adverse events. This follow up looks past the efficacy headline to the tolerability numbers, what they show, what they leave out, and the checkpoint that comes next.

Retatrutide vs Ozempic on the numbers

Lilly ran TRANSCEND-T2D-2 as an open label Phase 3 study in 1,298 adults with type 2 diabetes whose blood sugar was not controlled on metformin, with or without an SGLT2 inhibitor. Everyone started with an A1C between 7.0% and 10.5%. Participants were randomized 2:2:1 to a lower retatrutide dose, a higher retatrutide dose or Ozempic at its top approved strength. The main test was whether the higher dose was noninferior to Ozempic on A1C at 80 weeks, and retatrutide was started low and raised in steps toward each target. The company said the drug met the primary goal and every key secondary goal. Our first report on the readout covered the efficacy headline; this piece sets it beside the safety table.

In the retatrutide vs Ozempic comparison, both retatrutide arms cut A1C by an average of 2.2 percentage points against 1.8 points with Ozempic, Lilly reported. Weight fell 19.5% on the lower dose and 20.9% on the higher dose, versus 9.4% on Ozempic, from an average starting weight of 102.4 kg. The company also reported larger gains in non HDL cholesterol, triglycerides and systolic blood pressure. One detail matters for reading these figures. Lilly said every number in its release uses the efficacy estimand, which models results as if all randomized people had stayed on their assigned drug for 80 weeks without adding other glucose lowering medicine. Because more people left the retatrutide arms, an analysis that counts everyone could show a smaller gap, and Lilly has not released one.

Retatrutide side effects by dose

The most common retatrutide side effects were digestive, as with other incretin drugs. Diarrhea affected 28.3% on the lower dose and 32.7% on the higher dose, compared with 26.4% on Ozempic, while vomiting reached 15.0% on the higher dose against 13.2%. Nausea was nearly level across the arms, and constipation and dyspepsia were more frequent with Ozempic. Lilly said most events were mild to moderate and usually resolved during treatment. The clearest gap was in treatment discontinuation: 4.8% on the lower dose and 7.9% on the higher dose stopped because of adverse events, against 2.7% on Ozempic. Compared with Ozempic, the higher retatrutide dose nearly tripled the rate of stopping for side effects, yet it added only 1.4 points of weight loss over the lower dose.

Compared with Ozempic, the higher retatrutide dose nearly tripled the rate of stopping for side effects, yet it added only 1.4 points of weight loss over the lower dose.

A less familiar signal also rose with dose. Dysesthesia, an altered or unpleasant sense of touch on the skin, was reported in 4.8% and 6.5% of people on the two retatrutide doses compared with 2.7% on Ozempic. The release gives no separate severity breakdown for it, and urinary tract infections showed no dose pattern. For prescribers, the practical point is that the lower dose kept the same A1C drop and almost all of the weight effect with fewer dropouts, which may matter more than the top figure if the drug is approved. An earlier story on this site found that starting semaglutide high raised the risk of stopping early in US claims data, a reminder that tolerability shapes how drugs are used outside trials.

Why a triple agonist carries a trade off

Retatrutide is a single peptide that activates receptors for GIP, GLP-1 and glucagon. That is one more target than Lilly's tirzepatide and two more than semaglutide, which acts on GLP-1 alone. The idea is that adding glucagon signalling pushes weight and metabolic effects further. MedCity News noted that hitting more targets is meant to improve results but also tends to bring more side effects, especially the digestive problems that lead people to stop. Leerink Partners analyst David Risinger made a similar point in a client note, describing the higher dropout as an expected trade off. He said the tolerability was broadly in line with an earlier Lilly Phase 3 trial in people with obesity and type 2 diabetes, so the new study did not reveal a fresh problem.

The commercial reading is upbeat but remains a forecast. According to BioPharma Dive, Risinger wrote that the data strengthen the case for long term differentiation and support premium pricing before semaglutide's US patent expires in 2032. He projects annual retatrutide sales of $15 billion in 2032, above a Wall Street consensus of $10 billion, figures that assume an approval that has not happened. The same report said Novo Nordisk has yet to launch a dual acting drug and that its three target candidates sit in Phase 2. Lilly's Kenneth Custer said the company believes retatrutide, "if approved, could shift the treatment paradigm" for people with type 2 diabetes, obesity and related conditions. That is the company's view, not a trial finding.

What remains open before TRIUMPH 5

Several questions stay open until the full dataset appears. Lilly plans to show the full data at a scientific congress and in a journal paper, without giving a date. For now there are no confidence intervals, no estimates that count every randomized person and no breakdown of when dropouts happened. The trial was open label, so participants and doctors knew which drug was given, and that can colour how retatrutide side effects are reported. Ozempic was tested only at its top approved strength, so the study says nothing about how retatrutide compares with tirzepatide or other options. An extension period in which about 650 participants stay on retatrutide for another 24 weeks should add longer safety data, according to the company.

The next major checkpoint is TRIUMPH-5, an ongoing Phase 3 trial comparing retatrutide head to head with tirzepatide in adults with obesity, including some who also have type 2 diabetes. Risinger flagged it as the readout to watch, since it tests the triple agonist against Lilly's own dual agonist rather than an older GLP-1 drug. Lilly counts TRANSCEND-T2D-2 as the sixth Phase 3 study with strong efficacy for retatrutide, alongside results such as the sleep apnea substudies. Retatrutide is not approved by any regulator. Lilly states that anyone selling it to consumers is breaking the law, and gray market products carry real risks of mislabelling, wrong strength and contamination.

Conclusion

TRANSCEND-T2D-2 confirms that retatrutide beats the top Ozempic dose on A1C and weight in type 2 diabetes, and it puts numbers on the cost. Retatrutide side effects were mostly digestive, and stopping for adverse events rose from 2.7% on Ozempic to 7.9% on the higher dose. The lower dose delivered nearly the same benefit with fewer dropouts. The molecule stays in Phase 3, and the open label design and efficacy estimand mean the full paper and TRIUMPH-5 will say more. This is research reporting, not medical advice.